Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

is trial. Efficacy evaluations will include the measure of target lesions (per RECIST), and the quantization of symptom relief. Further details of this trial can be found at http://www.clinicaltrials.gov.

The other five sites currently participating in this Phase II trial are: 1) the Hematology Oncology Services of Arkansas in Little Rock, Arkansas, 2) the Dana-Farber Cancer Institute in Boston, MA. 3) Mount Sinai in New York City, 4) Lahey Clinic in Burlington, MA. and 5) Scott & White Memorial Hospital in Temple TX.

About Atiprimod

Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials: a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Callisto earlier announced in June, 2006 interim data from a Phase I trial of Atiprimod in advanced cancer patients. The patients who were entered into this trial had growing tumors and symptoms that were no longer controlled by the standard therapies utilized. During treatment, three of the five advanced carcinoid patients had measurable tumor regressions and loss of many of the debilitating symptoms of this disease.

About Carcinoid Cancer

Carcinoid tumors, or carcinoids, originate in hormone-producing cells of the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. Approximately 7,000 cases of carcinoid cancer are diag
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
(Date:11/26/2014)... Nov. 26, 2014  CARsgen, a leader in the ... to treat a variety of cancers, today announced the ... a China -based healthcare private equity ... focused on the development of new therapeutics for liver, ... Cancer Institute and Shanghai Renji Hospital, the company plans ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... November 27, 2014 An inventor from ... embarrassing fact of life, and she wants to lessen ... minutes later, I decided that there needed to be ... said. , Easy to use and producible in design ... a woman’s private areas throughout the day. It avoids ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... 2014 The founders of VIM & VIGR, ... high functioning compression socks, are proud to announce the debut ... innovative Gradient Pressure (TM) knitting technology that is designed to ... VIGR’s commitment to adding flair and style to a product ... caught the eye of a writer at The New ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... nifedipine therapy and placebo, researchers say , , WEDNESDAY, Nov. ... used to prevent premature birth when women go into ... at maintaining pregnancy, after the initial spell of preterm ... who conducted the first ever placebo-controlled test of nifedipine ...
... Media coverage of clinical trials does not contain the ... of the coverage received by pharmaceutical and herbal remedy ... Medicine , has revealed that it is rarely possible ... the described research. , Tania Bubela from the University ...
... The American Veterinary Medical,Association (AVMA) Executive Board voted to ... dogs -- ear cropping and tail,docking. , ... AVMA opposes ear cropping and tail,docking of dogs when done ... ear cropping and tail docking from breed standards." , ...
... DRRX ) announced today that management is scheduled to present ... -- 20th Annual Piper Jaffray Health ... -- RBC Capital Markets 2008 ... A live audio webcast of ...
... ingredients can mean healthier eating without the guilt, experts ... A few healthy substitutions in your Thanksgiving recipes can ... sacrificing the taste, says the American Medical Association. ... swapping out a few ingredients with healthier alternatives, you ...
... (Nasdaq: HLTH ) announced today the preliminary results ... of its common stock at a price of $8.80 per ... on November 25, 2008. Based on the preliminary count ... the tender offer, 86,145,082 shares of common stock (including approximately ...
Cached Medicine News:Health News:Drug to Prevent Preterm Labor Shows Little Benefit 2Health News:Misleading media coverage of medicine 2Health News:AVMA Revises Policy on Ear Cropping and Tail Docking 2Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Holiday Meals With a Calorie-Conscious Twist 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 3Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 4
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
...
Medicine Products: